The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of clinical primary tumor site (PTS) response to induction chemotherapy (IC) with APF (nab-paclitaxel, cisplatin, and 5-FU) or APF plus cetuximab (APF+Cetux) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Jessica C. Ley
No relevant relationships to disclose
Brian Nussenbaum
No relevant relationships to disclose
Jason Diaz
No relevant relationships to disclose
Jason Rich
No relevant relationships to disclose
Randal Paniello
No relevant relationships to disclose
Ravi Uppaluri
No relevant relationships to disclose
Wade L. Thorstad
No relevant relationships to disclose
Hiram Alberto Gay
No relevant relationships to disclose
Toni Rachocki
No relevant relationships to disclose
Jaisy Varges
No relevant relationships to disclose
Tanya Marya Wildes
No relevant relationships to disclose
Loren S. Michel
No relevant relationships to disclose
Douglas Adkins
Research Funding - Celgene; Lilly